home / press / releases

Menu
  • Search all tables

releases: https://www.manchin.senate.gov/newsroom/press-releases/manchin-announces-legislative-repeal-for-2016-law-preventing-aggressive-dea-enforcement-of-opioid-distributors-and-manufacturers

One row per release. Full-text search runs over title + body text.

Data license: MIT · Data source: dwillis/congress-press

This data as json

url title date year month party chamber state member_name bioguide_id domain scraper source date_source text has_text collected_at updated_at
https://www.manchin.senate.gov/newsroom/press-releases/manchin-announces-legislative-repeal-for-2016-law-preventing-aggressive-dea-enforcement-of-opioid-distributors-and-manufacturers MANCHIN ANNOUNCES LEGISLATIVE REPEAL FOR 2016 LAW PREVENTING AGGRESSIVE DEA ENFORCEMENT OF OPIOID DISTRIBUTORS AND MANUFACTURERS 2017-10-16 2017 2017-10 Democrat House WV Joe Manchin M001183 www.manchin.senate.gov     legacy October 16, 2017 MANCHIN ANNOUNCES LEGISLATIVE REPEAL FOR 2016 LAW PREVENTING AGGRESSIVE DEA ENFORCEMENT OF OPIOID DISTRIBUTORS AND MANUFACTURERS Washington, D.C. – U.S. Senator Joe Manchin (D-WV) today introduced legislation repealing the Ensuring Patient Access and Effective Drug Enforcement Act of 2016 after the Washington Post report indicated that the legislation has dramatically restricted the ability of the Drug Enforcement Administration (DEA) to crack down on opioid distributors and manufacturers suspected of wrongdoing. “I am horrified by how harmful this bill has been for our efforts to effectively fight the opioid epidemic and now it’s time to make it right,” Senator Manchin. “I introduced legislation to repeal this horrible bill and reinstate the DEA’s ability to stop opioid distributors and manufacturers who are endangering the American people. The DEA is one of our first lines of defense against this all-consuming disease. West Virginia’s families and communities deserve a DEA that will protect them, not pharmaceutical companies.” The 2016 bill purported to “improve enforcement efforts related to prescription drug diversion and abuse” by altering DEA procedures for revoking or suspending registrations for opioid distributors under the Controlled Substances Act. However, the effect of these changes, according to reports, has been to significantly curtail the ability of DEA to bring enforcement actions against drug distributors and manufacturers. Manchin also sent a letter to the White House demanding that Rep. Tom Marino’s nomination be pulled from consideration to lead the White House Office of National Drug Control Policy. He urged swift action in response to the Washington Post article outlining Rep. Marino’s involvement in passing a bill weakening the Drug Enforcement Administration’s (DEA) authority to stop companies from distributing opioids. To read the letter Senator Manchin sent to the White House click here. ### Print Email Tweet Next Article Previous Article 1 2026-03-30T12:14:52Z 2026-03-30T12:14:52Z
Powered by Datasette · Queries took 1.609ms · Data license: MIT · Data source: dwillis/congress-press